The DAC (Degrader Antibody Conjugate) technology platform is our core next-generation targeted therapy technology. It innovatively couples highly specific antibodies with catalytic protein degraders (such as molecular glues), combining the dual advantages of both: achieving targeted delivery to tissues and cells through the "precise navigation" of antibodies, and then utilizing the intracellular "catalytic degradation" mechanism of degraders to directly eliminate pathogenic target proteins.This approach breaks through the limitations of traditional "undruggable" targets, achieving a therapeutic leap from inhibition to clearance and improving safety.